Concepts (245)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Analgesics, Opioid | 7 | 2025 | 252 | 1.550 |
Why?
|
| Opioid-Related Disorders | 7 | 2025 | 69 | 1.400 |
Why?
|
| Bayes Theorem | 10 | 2025 | 85 | 1.140 |
Why?
|
| Community-Based Participatory Research | 2 | 2025 | 120 | 0.830 |
Why?
|
| Ohio | 8 | 2025 | 64 | 0.830 |
Why?
|
| Decision Making | 1 | 2023 | 202 | 0.680 |
Why?
|
| Humans | 48 | 2025 | 32779 | 0.670 |
Why?
|
| Patient Admission | 2 | 2019 | 59 | 0.620 |
Why?
|
| Sexually Transmitted Diseases | 3 | 2025 | 47 | 0.620 |
Why?
|
| HIV Infections | 4 | 2025 | 424 | 0.620 |
Why?
|
| Adult | 23 | 2025 | 9547 | 0.600 |
Why?
|
| Research Design | 2 | 2023 | 331 | 0.580 |
Why?
|
| Population Surveillance | 1 | 2019 | 128 | 0.570 |
Why?
|
| Male | 35 | 2025 | 19624 | 0.540 |
Why?
|
| Female | 35 | 2025 | 20249 | 0.530 |
Why?
|
| Hepatitis C | 3 | 2025 | 45 | 0.490 |
Why?
|
| Adolescent | 12 | 2025 | 3627 | 0.470 |
Why?
|
| Data Collection | 1 | 2015 | 185 | 0.460 |
Why?
|
| Middle Aged | 21 | 2025 | 12115 | 0.450 |
Why?
|
| Diabetes Mellitus | 4 | 2022 | 422 | 0.440 |
Why?
|
| Young Adult | 11 | 2025 | 2730 | 0.420 |
Why?
|
| Substance-Related Disorders | 2 | 2024 | 131 | 0.390 |
Why?
|
| Rural Population | 2 | 2025 | 286 | 0.390 |
Why?
|
| Appalachian Region | 4 | 2025 | 20 | 0.380 |
Why?
|
| United States | 7 | 2025 | 4108 | 0.350 |
Why?
|
| Coronary Disease | 3 | 2022 | 214 | 0.340 |
Why?
|
| Hydrocortisone | 2 | 2021 | 57 | 0.330 |
Why?
|
| Length of Stay | 3 | 2019 | 329 | 0.310 |
Why?
|
| Blood Glucose | 3 | 2020 | 494 | 0.290 |
Why?
|
| Upper Extremity | 2 | 2019 | 59 | 0.290 |
Why?
|
| Telemedicine | 3 | 2025 | 117 | 0.290 |
Why?
|
| Aged | 15 | 2025 | 10534 | 0.280 |
Why?
|
| Bacterial Infections | 2 | 2018 | 51 | 0.270 |
Why?
|
| Homosexuality, Male | 2 | 2025 | 105 | 0.260 |
Why?
|
| Prevalence | 4 | 2024 | 1002 | 0.260 |
Why?
|
| Stroke | 3 | 2022 | 609 | 0.250 |
Why?
|
| Emergency Service, Hospital | 3 | 2019 | 490 | 0.250 |
Why?
|
| Licensure | 1 | 2025 | 6 | 0.230 |
Why?
|
| Peer Group | 1 | 2025 | 45 | 0.230 |
Why?
|
| Automobile Driving | 1 | 2025 | 26 | 0.230 |
Why?
|
| Pharmacies | 1 | 2025 | 16 | 0.230 |
Why?
|
| Naloxone | 1 | 2025 | 29 | 0.230 |
Why?
|
| Narcotic Antagonists | 1 | 2025 | 43 | 0.230 |
Why?
|
| African Americans | 3 | 2021 | 1424 | 0.220 |
Why?
|
| Urban Population | 1 | 2025 | 93 | 0.220 |
Why?
|
| Heroin | 1 | 2024 | 21 | 0.220 |
Why?
|
| Placenta | 1 | 2024 | 75 | 0.210 |
Why?
|
| Physicians | 1 | 2025 | 165 | 0.200 |
Why?
|
| Accidents, Traffic | 1 | 2025 | 197 | 0.200 |
Why?
|
| Health Status Disparities | 1 | 2024 | 134 | 0.190 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2024 | 754 | 0.190 |
Why?
|
| Age Factors | 6 | 2025 | 1197 | 0.190 |
Why?
|
| Hospitals, Pediatric | 2 | 2019 | 47 | 0.190 |
Why?
|
| Seroepidemiologic Studies | 1 | 2021 | 10 | 0.180 |
Why?
|
| Retrospective Studies | 8 | 2020 | 3700 | 0.170 |
Why?
|
| Prognosis | 3 | 2019 | 1544 | 0.170 |
Why?
|
| Child | 7 | 2020 | 2471 | 0.160 |
Why?
|
| Prospective Studies | 6 | 2024 | 2327 | 0.160 |
Why?
|
| Advance Care Planning | 1 | 2020 | 15 | 0.160 |
Why?
|
| Video Games | 1 | 2019 | 5 | 0.160 |
Why?
|
| Cerebrospinal Fluid Proteins | 1 | 2019 | 4 | 0.160 |
Why?
|
| Guillain-Barre Syndrome | 1 | 2019 | 7 | 0.160 |
Why?
|
| Acute Disease | 2 | 2018 | 259 | 0.160 |
Why?
|
| Allostasis | 1 | 2019 | 12 | 0.150 |
Why?
|
| Adiposity | 1 | 2021 | 198 | 0.150 |
Why?
|
| Capital Punishment | 1 | 2019 | 1 | 0.150 |
Why?
|
| Insulin Resistance | 1 | 2022 | 469 | 0.150 |
Why?
|
| Aldosterone | 1 | 2019 | 27 | 0.150 |
Why?
|
| Off-Label Use | 1 | 2019 | 12 | 0.150 |
Why?
|
| Deep Brain Stimulation | 1 | 2019 | 49 | 0.150 |
Why?
|
| Suicide, Attempted | 1 | 2019 | 33 | 0.150 |
Why?
|
| Sodium Channel Blockers | 1 | 2018 | 6 | 0.150 |
Why?
|
| Myotonic Disorders | 1 | 2018 | 3 | 0.150 |
Why?
|
| Lethargy | 1 | 2018 | 2 | 0.150 |
Why?
|
| Anaphylaxis | 1 | 2019 | 12 | 0.150 |
Why?
|
| Methicillin Resistance | 1 | 2019 | 22 | 0.150 |
Why?
|
| Consciousness Disorders | 1 | 2018 | 5 | 0.150 |
Why?
|
| Charcot-Marie-Tooth Disease | 1 | 2018 | 8 | 0.150 |
Why?
|
| Nervous System Diseases | 1 | 2019 | 41 | 0.150 |
Why?
|
| Cohort Studies | 5 | 2022 | 1844 | 0.150 |
Why?
|
| Exercise Movement Techniques | 1 | 2018 | 3 | 0.150 |
Why?
|
| Staphylococcus aureus | 1 | 2019 | 54 | 0.150 |
Why?
|
| Muscular Diseases | 1 | 2018 | 23 | 0.150 |
Why?
|
| Paresis | 1 | 2018 | 12 | 0.150 |
Why?
|
| Child Abuse | 1 | 2019 | 28 | 0.150 |
Why?
|
| Lymphoma, T-Cell, Cutaneous | 1 | 2018 | 4 | 0.150 |
Why?
|
| Motor Neurons | 1 | 2018 | 40 | 0.150 |
Why?
|
| Foot | 1 | 2018 | 41 | 0.150 |
Why?
|
| Polymerase Chain Reaction | 1 | 2019 | 199 | 0.150 |
Why?
|
| Killer Cells, Natural | 1 | 2018 | 24 | 0.140 |
Why?
|
| Office Visits | 1 | 2019 | 73 | 0.140 |
Why?
|
| Fever | 1 | 2018 | 60 | 0.140 |
Why?
|
| Child, Preschool | 5 | 2019 | 1276 | 0.140 |
Why?
|
| Parkinson Disease | 1 | 2019 | 89 | 0.140 |
Why?
|
| Pediatrics | 1 | 2020 | 155 | 0.140 |
Why?
|
| Staphylococcal Infections | 1 | 2019 | 78 | 0.140 |
Why?
|
| Muscle Contraction | 1 | 2018 | 113 | 0.140 |
Why?
|
| Longitudinal Studies | 4 | 2022 | 779 | 0.140 |
Why?
|
| Exercise Test | 1 | 2019 | 223 | 0.140 |
Why?
|
| Heart Diseases | 1 | 2019 | 116 | 0.140 |
Why?
|
| Polyradiculoneuropathy, Chronic Inflammatory Demyelinating | 1 | 2017 | 6 | 0.140 |
Why?
|
| Dermatomyositis | 1 | 2017 | 19 | 0.140 |
Why?
|
| Myasthenia Gravis | 1 | 2017 | 15 | 0.140 |
Why?
|
| Myotonia Congenita | 1 | 2017 | 2 | 0.140 |
Why?
|
| Cardiovascular Agents | 1 | 2017 | 22 | 0.130 |
Why?
|
| Residence Characteristics | 1 | 2019 | 197 | 0.130 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2017 | 42 | 0.130 |
Why?
|
| Emergency Medical Services | 1 | 2019 | 181 | 0.130 |
Why?
|
| Atherosclerosis | 1 | 2022 | 788 | 0.120 |
Why?
|
| Depression | 1 | 2019 | 448 | 0.120 |
Why?
|
| Antihypertensive Agents | 1 | 2019 | 352 | 0.120 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2017 | 203 | 0.120 |
Why?
|
| Data Interpretation, Statistical | 1 | 2015 | 114 | 0.110 |
Why?
|
| Time Factors | 3 | 2019 | 2180 | 0.110 |
Why?
|
| Muscle, Skeletal | 1 | 2018 | 524 | 0.110 |
Why?
|
| Ribonucleases | 1 | 2012 | 5 | 0.100 |
Why?
|
| Proteus mirabilis | 1 | 2012 | 2 | 0.100 |
Why?
|
| Uropathogenic Escherichia coli | 1 | 2012 | 6 | 0.100 |
Why?
|
| Quality of Life | 1 | 2018 | 961 | 0.100 |
Why?
|
| Anti-Infective Agents | 1 | 2012 | 44 | 0.090 |
Why?
|
| Organogenesis | 1 | 2012 | 18 | 0.090 |
Why?
|
| Infant | 3 | 2019 | 1081 | 0.090 |
Why?
|
| Skin Tests | 1 | 2011 | 12 | 0.090 |
Why?
|
| Risk Factors | 4 | 2019 | 3974 | 0.090 |
Why?
|
| Hypersensitivity | 1 | 2011 | 25 | 0.090 |
Why?
|
| Cardiovascular Diseases | 1 | 2019 | 1140 | 0.090 |
Why?
|
| Severity of Illness Index | 3 | 2018 | 881 | 0.080 |
Why?
|
| Urinary Bladder | 1 | 2012 | 183 | 0.080 |
Why?
|
| Disease Models, Animal | 2 | 2024 | 1012 | 0.070 |
Why?
|
| Electromyography | 2 | 2018 | 60 | 0.070 |
Why?
|
| Hand Strength | 2 | 2018 | 101 | 0.070 |
Why?
|
| Respiratory Tract Infections | 2 | 2018 | 38 | 0.070 |
Why?
|
| Urinary Tract Infections | 2 | 2018 | 46 | 0.070 |
Why?
|
| Sex Factors | 2 | 2019 | 675 | 0.070 |
Why?
|
| Multivariate Analysis | 2 | 2019 | 682 | 0.070 |
Why?
|
| Accidental Falls | 2 | 2019 | 221 | 0.070 |
Why?
|
| Cross-Sectional Studies | 2 | 2022 | 1572 | 0.070 |
Why?
|
| Pilot Projects | 2 | 2018 | 565 | 0.060 |
Why?
|
| Microbial Sensitivity Tests | 2 | 2019 | 80 | 0.060 |
Why?
|
| Animals | 4 | 2024 | 7570 | 0.060 |
Why?
|
| Incidence | 2 | 2019 | 1238 | 0.060 |
Why?
|
| Tissue Adhesions | 1 | 2024 | 12 | 0.060 |
Why?
|
| Drug Users | 1 | 2024 | 14 | 0.060 |
Why?
|
| Hyaluronic Acid | 1 | 2024 | 54 | 0.050 |
Why?
|
| Aged, 80 and over | 3 | 2019 | 4032 | 0.050 |
Why?
|
| Random Allocation | 1 | 2024 | 229 | 0.050 |
Why?
|
| Central Nervous System Stimulants | 1 | 2024 | 78 | 0.050 |
Why?
|
| Massachusetts | 1 | 2023 | 26 | 0.050 |
Why?
|
| Models, Statistical | 1 | 2024 | 180 | 0.050 |
Why?
|
| Medicare | 1 | 2025 | 213 | 0.050 |
Why?
|
| Stem Cell Transplantation | 1 | 2024 | 212 | 0.050 |
Why?
|
| Follow-Up Studies | 2 | 2019 | 2282 | 0.050 |
Why?
|
| Sexual Behavior | 1 | 2023 | 125 | 0.050 |
Why?
|
| Feasibility Studies | 1 | 2023 | 308 | 0.050 |
Why?
|
| Reproducibility of Results | 2 | 2017 | 767 | 0.050 |
Why?
|
| Parathyroid Hormone | 1 | 2022 | 47 | 0.050 |
Why?
|
| Vitamins | 1 | 2022 | 73 | 0.050 |
Why?
|
| Pregnancy | 1 | 2024 | 981 | 0.040 |
Why?
|
| Glucose | 1 | 2022 | 184 | 0.040 |
Why?
|
| Vitamin D | 1 | 2022 | 189 | 0.040 |
Why?
|
| Rats | 1 | 2024 | 1606 | 0.040 |
Why?
|
| Waist Circumference | 1 | 2021 | 92 | 0.040 |
Why?
|
| Intra-Abdominal Fat | 1 | 2021 | 63 | 0.040 |
Why?
|
| Adiponectin | 1 | 2021 | 103 | 0.040 |
Why?
|
| Glucose Intolerance | 1 | 2020 | 46 | 0.040 |
Why?
|
| North Carolina | 1 | 2024 | 1546 | 0.040 |
Why?
|
| Saliva | 1 | 2020 | 39 | 0.040 |
Why?
|
| Circadian Rhythm | 1 | 2020 | 45 | 0.040 |
Why?
|
| Algorithms | 1 | 2023 | 511 | 0.040 |
Why?
|
| Fasting | 1 | 2020 | 94 | 0.040 |
Why?
|
| Hemiplegia | 1 | 2019 | 12 | 0.040 |
Why?
|
| Mice | 2 | 2018 | 2511 | 0.040 |
Why?
|
| Documentation | 1 | 2020 | 47 | 0.040 |
Why?
|
| Treatment Outcome | 2 | 2017 | 3437 | 0.040 |
Why?
|
| Glasgow Coma Scale | 1 | 2019 | 28 | 0.040 |
Why?
|
| Mississippi | 1 | 2019 | 35 | 0.040 |
Why?
|
| Respiration, Artificial | 1 | 2019 | 98 | 0.040 |
Why?
|
| Emergency Medical Service Communication Systems | 1 | 2019 | 3 | 0.040 |
Why?
|
| DNA, Bacterial | 1 | 2019 | 29 | 0.040 |
Why?
|
| Stiff-Person Syndrome | 1 | 2018 | 1 | 0.040 |
Why?
|
| Myelin Proteins | 1 | 2018 | 4 | 0.040 |
Why?
|
| Torque | 1 | 2018 | 20 | 0.040 |
Why?
|
| Gastroenteritis | 1 | 2018 | 12 | 0.040 |
Why?
|
| Superoxide Dismutase | 1 | 2018 | 42 | 0.040 |
Why?
|
| Toes | 1 | 2018 | 16 | 0.040 |
Why?
|
| Observer Variation | 1 | 2019 | 96 | 0.040 |
Why?
|
| Muscle Weakness | 1 | 2018 | 36 | 0.040 |
Why?
|
| K562 Cells | 1 | 2018 | 4 | 0.040 |
Why?
|
| Disability Evaluation | 1 | 2019 | 238 | 0.040 |
Why?
|
| Regression Analysis | 1 | 2019 | 288 | 0.040 |
Why?
|
| Chronic Disease | 1 | 2020 | 410 | 0.040 |
Why?
|
| Bacterial Proteins | 1 | 2019 | 89 | 0.040 |
Why?
|
| Neuromuscular Junction | 1 | 2018 | 66 | 0.040 |
Why?
|
| Amyotrophic Lateral Sclerosis | 1 | 2018 | 61 | 0.040 |
Why?
|
| Poverty | 1 | 2019 | 116 | 0.040 |
Why?
|
| Triage | 1 | 2019 | 75 | 0.040 |
Why?
|
| Guideline Adherence | 1 | 2019 | 120 | 0.040 |
Why?
|
| Mice, Transgenic | 1 | 2018 | 258 | 0.040 |
Why?
|
| Drug Therapy, Combination | 1 | 2019 | 289 | 0.040 |
Why?
|
| Cause of Death | 1 | 2019 | 240 | 0.030 |
Why?
|
| Plasmapheresis | 1 | 2017 | 11 | 0.030 |
Why?
|
| Action Potentials | 1 | 2018 | 186 | 0.030 |
Why?
|
| Mortality | 1 | 2019 | 124 | 0.030 |
Why?
|
| Patient Discharge | 1 | 2019 | 204 | 0.030 |
Why?
|
| Autoimmunity | 1 | 2017 | 34 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2019 | 764 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2019 | 887 | 0.030 |
Why?
|
| Guidelines as Topic | 1 | 2017 | 49 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2018 | 525 | 0.030 |
Why?
|
| Poisson Distribution | 1 | 2016 | 16 | 0.030 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2017 | 121 | 0.030 |
Why?
|
| Disease Progression | 1 | 2018 | 594 | 0.030 |
Why?
|
| Infant, Newborn | 1 | 2019 | 694 | 0.030 |
Why?
|
| Pain | 1 | 2018 | 294 | 0.030 |
Why?
|
| Geriatric Assessment | 1 | 2018 | 388 | 0.030 |
Why?
|
| Anti-Bacterial Agents | 1 | 2019 | 332 | 0.030 |
Why?
|
| Hospital Mortality | 1 | 2017 | 205 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2018 | 789 | 0.030 |
Why?
|
| Immunosuppressive Agents | 1 | 2017 | 241 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2016 | 188 | 0.030 |
Why?
|
| Comorbidity | 1 | 2017 | 573 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2016 | 369 | 0.030 |
Why?
|
| Obesity | 1 | 2022 | 1152 | 0.030 |
Why?
|
| European Continental Ancestry Group | 1 | 2019 | 1163 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2016 | 622 | 0.030 |
Why?
|
| Myocardial Infarction | 1 | 2019 | 483 | 0.030 |
Why?
|
| Antimicrobial Cationic Peptides | 1 | 2012 | 14 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 1 | 2012 | 96 | 0.020 |
Why?
|
| Heart Failure | 1 | 2019 | 695 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2012 | 247 | 0.020 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 2 | 1 | 2012 | 4 | 0.020 |
Why?
|
| Mice, Mutant Strains | 1 | 2012 | 49 | 0.020 |
Why?
|
| Muscle, Smooth | 1 | 2012 | 69 | 0.020 |
Why?
|
| Urothelium | 1 | 2012 | 55 | 0.020 |
Why?
|
| Gene Expression | 1 | 2012 | 334 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2017 | 1460 | 0.020 |
Why?
|
| Antigens, Dermatophagoides | 1 | 2011 | 1 | 0.020 |
Why?
|
| Pyroglyphidae | 1 | 2011 | 1 | 0.020 |
Why?
|
| Trees | 1 | 2011 | 3 | 0.020 |
Why?
|
| Antigens, Plant | 1 | 2011 | 4 | 0.020 |
Why?
|
| Poaceae | 1 | 2011 | 2 | 0.020 |
Why?
|
| Organ Size | 1 | 2012 | 219 | 0.020 |
Why?
|
| Allergens | 1 | 2011 | 15 | 0.020 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2012 | 134 | 0.020 |
Why?
|
| Peptide Fragments | 1 | 2012 | 403 | 0.020 |
Why?
|